Clinical Trial Update: MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study of the MEK inhibitor AZD6244 (selumetinib) in patients with stage III or stage IV melanoma has completed, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AZD6244 (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage III Skin Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2015-08-11